Tennessee · Schedule I · The active bill is about ibogaine
Tennessee's psychedelic debate in 2026 runs through ibogaine, not psilocybin.
Tennessee is the most restrictive state in this group on psilocybin: it remains fully Schedule I, with no decriminalization, no therapeutic-access framework, and no enacted research fund. What is striking is where the state's psychedelic-policy energy has actually gone. The live 2026 effort is the HOPE Treatment Act (SB 2149 / HB 2075) — a bill to fund FDA-authorized clinical trials of ibogaine, a different psychedelic, for conditions like PTSD and opioid-use disorder. Advocates, including military veterans, rallied for it at the Capitol on February 24, 2026. The bill keeps ibogaine Schedule I while permitting tightly regulated research. Psilocybin, meanwhile, has no comparable live vehicle in the Tennessee legislature.
90-second quick read · research companion
Need the full research version?
This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.
Tennessee’s actual conversation
The active path isn’t psilocybin
Tennessee keeps psilocybin firmly Schedule I with no reform in motion. Its live 2026 legislation — the HOPE Act — funds ibogaine clinical trials instead. The fork below shows the two diverging paths.
Where the paths diverge
Tennessee psychedelic policy
Psilocybin
Schedule I, no movement
Fully Schedule I. No decriminalization, no access, no research fund, and no active bill.
StalledIbogaine
HOPE Treatment Act
SB 2149 / HB 2075 would fund ibogaine clinical trials; a Capitol forum was held Feb 24 2026.
Active 2026Why this shape
A different compound carrying the conversation
Tennessee illustrates that “psychedelic policy” is not one thing. The state's reform energy in 2026 is concentrated on ibogaine — driven by veterans and addiction-treatment advocates — through the HOPE Treatment Act. Psilocybin is not the vehicle here. For anyone tracking Tennessee, the honest summary is that the active conversation is about a different molecule, and psilocybin's status is simple and unchanged: Schedule I, no reform.
- Psilocybin: fully Schedule I — no decriminalization, no access framework, no research fund. Possession, cultivation, and sale are criminal offenses.
- Ibogaine: the live bill — the HOPE Treatment Act (SB 2149/HB 2075) would fund FDA-authorized ibogaine clinical trials; advocates rallied at the Capitol on Feb. 24, 2026.
- Veterans driving it — the ibogaine effort is led by veterans and addiction-treatment advocates focused on PTSD, traumatic brain injury, and opioid-use disorder.
Four cities
Where Tennessee's debate plays out
Tennessee's psychedelic-policy activity centers on its major metros. Nashville is the capital, where the HOPE Act and its February 2026 Capitol forum took place. Memphis is the largest city and a major medical center. Knoxville anchors East Tennessee and the University of Tennessee. Chattanooga rounds out the state's metro corridor.
Nashville
Capital · HOPE Act forum
690K. State capital, where the HOPE Treatment Act is under consideration and where advocates held a Capitol ibogaine forum in February 2026.
Nashville pageMemphis
Largest city · medical center
630K. Tennessee's largest city and a major medical center. Some drug-policy reform discussion occurs here, but no psilocybin ordinance is in effect.
Memphis pageKnoxville
East TN · University of Tennessee
190K. Anchors East Tennessee and the University of Tennessee. No state research program means any psilocybin work would be federally authorized.
Knoxville pageChattanooga
SE TN · metro corridor
185K. Southeast Tennessee metro on the Georgia line. Psilocybin is fully Schedule I, mirroring strict-neighbor Georgia across the border.
Chattanooga pageCommon questions
Tennessee psilocybin FAQ
Q · 01
Is psilocybin legal in Tennessee?
No. Psilocybin is fully Schedule I in Tennessee. There is no decriminalization, no therapeutic-access framework, and no enacted research fund. It is the most restrictive state among its regional peers on psilocybin.
Q · 02
What is the HOPE Treatment Act?
The HOPE (Helping Open Pathways to Effective) Treatment Act, SB 2149/HB 2075, is a 2026 bill to fund FDA-authorized clinical trials of ibogaine — not psilocybin — for conditions like PTSD and opioid-use disorder. It would keep ibogaine Schedule I while permitting tightly regulated research.
Q · 03
Why is Tennessee's reform about ibogaine, not psilocybin?
The state's 2026 psychedelic-policy energy, driven largely by veterans and addiction-treatment advocates, is focused on ibogaine through the HOPE Act. Psilocybin has no comparable active bill in the Tennessee legislature, so the live conversation is about a different compound.
Q · 04
Has any Tennessee city decriminalized psilocybin?
No. Tennessee has no statewide reform and no city has enacted a deprioritization ordinance. Some advocacy and harm-reduction discussion occurs in Nashville and Memphis, but no municipal psilocybin ordinance is in effect.
While psilocybin stays Schedule I
iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.